Regadenoson
LEXISCAN
What it isSelective adenosine A2A agonist; pharmacologic cardiac stress testing.
Why this oneA single fixed-dose bolus replaces a weight-based adenosine infusion, with less bronchospasm from A2B and A3 sparing.
What limits itSeizures and, rarely, infarction can occur. Caffeine within twelve hours blunts it; aminophylline reverses it.
FDA-approved for
- myocardial perfusion imaging (stress agent) (2008)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Pharmacologic stress agent for myocardial perfusion imaging | Adults | 0.4 mg (5 mL) IV once | 0.4 mg IV once | 0.4 mg IV once |
Renal No adjustment needed
Hepatic Undefined
Instructions
- Give as IV injection within 10 sec into a peripheral vein (22 G or larger)
- Follow immediately with 5 mL saline flush
- Inject radionuclide 10-20 sec after the flush
- Avoid methylxanthines (caffeine, tea, aminophylline, theophylline) for >=12 h before
Contraindications
- Second- or third-degree AV block without a functioning pacemaker
- Sinus node dysfunction without a functioning pacemaker
Cautions
- Myocardial ischemia (fatal cardiac events); have resuscitation equipment ready
- SA/AV nodal block
- Atrial fibrillation/flutter
- Hypersensitivity/anaphylaxis
- Hypotension
- Hypertension
- Bronchoconstriction
- Seizure
- Stroke
Adverse reactions
- Dyspnea
- Headache
- Flushing
- Chest discomfort
- Dizziness
- Angina
- Chest pain
- Nausea
Pregnancy No human data; adverse fetal outcomes only at maternally toxic doses in animals
Lactation No human data; pump and discard milk for 10 h after administration
NO BOXED WARNINGS
Principal riskSeizures and, rarely, infarction
Classes and tags
Clinical profile
Mechanism of action: Regadenoson ballicule
